Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26042916 | 0.83 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 | |
| SCHEMBL12772837 | 0.81 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 | |
| SCHEMBL3436969 | 0.81 | L3MBTL1 (0.46) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 | |
| SCHEMBL23269640 | 0.79 | L3MBTL1 (0.44) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 | |
| SCHEMBL26577467 | 0.79 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 | |
| SCHEMBL14307143 | 0.79 | L3MBTL1 (0.44) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 | |
| SCHEMBL26042817 | 0.77 | KDM4E (0.33) | L3MBTL3L3MBTL1ALDH1A1NCF1HRH3 | |
| SCHEMBL9945787 | 0.77 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1ALDH1A1HRH3 | |
| SCHEMBL29904663 | 0.77 | KHK (0.36) | L3MBTL3L3MBTL1SMN1; SMN2HRH3 | |
| SCHEMBL22456378 | 0.77 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1ALDH1A1PIM1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | L3MBTL3 3162/4885L3MBTL1 2714/4885ALDH1A1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.